U.K. adopts UCB and kitchenware maker OXO's Cimzia self-injection pen

A self-injection pen prefilled with Brussels-based UCB’s Cimzia (certolizumab pegol) has been made available this week in the U.K. after a positive opinion from the EMA.

UCB developed the AutoClicks pen along with a New York company not normally known for such medical devices: kitchenware maker OXO.

With OXO’s Good Grips line of ergonomic, nonslip utensils and the like, the company helped UCB--along with core technology license provider Bespak--deliver a pen with button-free administration and a wide, nonslip handle. The company says this helps people with disabilities use the pen more easily.

Free Webinar

Building a Flexible, Challenge Resistant and Patient Centric Clinical Supply Chain

The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. In this webinar, learn the benefits of utilizing demand-led supply and direct-to-patient distribution models in the clinical supply chain, as well as how they can be used to both improve flexibility and better align with patient needs. Register today!

The cost to the NHS for treating a patient with the device is £715 for two doses of 200 mg.

For patients with rheumatoid arthritis, a normal pen can be difficult to use. Ailsa Bosworth, CEO of the National Rheumatoid Arthritis Society and a patient herself, said: “It is difficult for people who do not suffer from this disease to understand just how challenging doing the ordinary things in daily life can be, more so for those with painful and swollen joints. Trying to grip an everyday object such as a kitchen gadget can cause immense pain. So we welcome any innovation that can help make the lives of RA patients more comfortable while they manage their condition."

Read more on

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.